Dermata Therapeutics, Inc. DRMA 深 滬
等待開盤 09-18 09:30:00 美东时间
5.58
-0.325
-5.50%
華盛通- 最 高5.90
- 今 開5.90
- 成交量 8.23万股
- 最 低 5.41
- 昨 收 5.905
- 總市值 380.33万
- 52周最高 23.70
- 市盈率 靜 --
- 換手率 12.08%
- 52周最低 5.0413
- 委 比 79.59%
- 總股本 68.16万
- 歷史最高 16680.00
- 量 比 1.04
- 振 幅 8.30%
- 歷史最低 5.41
- 每 手 1
- 風險率 3.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Dermata Therapeutics Presents Promising Phase 3 Trial Results
Dermata Therapeutics ( ($DRMA) ) has provided an update. On September 17, 2025,...
09-17 18:29
Dermata Therapeutics Announces Strategic Pivot To Prioritize Development And Distribution Of OTC Pharmaceutical Dermatology Focused Products
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced a bold strategic pivot to prioritize the development and
09-10 20:09
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Biodesix (NASDAQ:BDSX) shares increased by 21.6% to $0.52 during Wedne...
09-04 05:06
Dermata Therapeutics Regains Nasdaq Compliance by August 2025
The latest announcement is out from Dermata Therapeutics ( ($DRMA) ). On May 14...
08-26 05:32
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $10
Maxim Group analyst Anthony Vendetti maintains Dermata Therapeutics (NASDAQ:DRMA) with a Buy and lowers the price target from $30 to $10.
08-22 00:32
Australian Patent Office Dermata Therapeutics Patent Application For DMT410 Program For Hyperhidrosis Titled "Compositions for the treatment of skin conditions," (Australian Patent No. 2109284621)
- This is the Company's second granted patent for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -- The Company recently entered into a Clinical Trial Collaboration
07-08 20:11
Dermata Faces Nasdaq Delisting Risk, Plans Stock Split
Dermata Therapeutics ( ($DRMA) ) has issued an announcement. On May 14, 2025, D...
07-08 05:49
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers ENDRA Life Sciences (NASDAQ:NDRA) stock increased by 50.4% to $5.2 dur...
07-08 05:06
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $3
Maxim Group analyst Anthony Vendetti maintains Dermata Therapeutics (NASDAQ:DRMA) with a Buy and lowers the price target from $6 to $3.
05-21 22:51
